ID   IGROV-1/Pt1
AC   CVCL_EQ62
SY   IGROV-1/Pt 1; IGROV1/Pt1
DR   cancercelllines; CVCL_EQ62
DR   IARC_TP53; 5445
DR   Wikidata; Q54897388
RX   PubMed=8564971;
RX   PubMed=9636834;
CC   Population: Caucasian.
CC   Doubling time: 33 +- 2 hours (PubMed=9636834).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Leu (c.808T>C); ClinVar=VCV000634778; Zygosity=Heterozygous (PubMed=8564971).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=8564971).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=8564971;
RA   Perego P., Giarola M., Righetti S.C., Supino R., Caserini C.,
RA   Delia D., Pierotti M.A., Miyashita T., Reed J.C., Zunino F.;
RT   "Association between cisplatin resistance and mutation of p53 gene and
RT   reduced bax expression in ovarian carcinoma cell systems.";
RL   Cancer Res. 56:556-562(1996).
//
RX   PubMed=9636834; DOI=10.1023/A:1008265012435;
RA   Perego P., Romanelli S., Carenini N., Magnani I., Leone R.,
RA   Bonetti A., Paolicchi A., Zunino F.;
RT   "Ovarian cancer cisplatin-resistant cell lines: multiple changes
RT   including collateral sensitivity to taxol.";
RL   Ann. Oncol. 9:423-430(1998).
//